Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.67 Average Price Target from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $5.67.

SGMO has been the topic of a number of research analyst reports. StockNews.com initiated coverage on Sangamo Therapeutics in a report on Saturday, April 27th. They set a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, May 15th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC bought a new position in shares of Sangamo Therapeutics in the 3rd quarter worth $26,000. State Board of Administration of Florida Retirement System increased its position in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Sangamo Therapeutics by 255.2% during the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 63,612 shares during the last quarter. Finally, Golden State Equity Partners increased its position in shares of Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Trading Down 3.7 %

Shares of SGMO opened at $0.60 on Friday. The company has a market cap of $123.51 million, a price-to-earnings ratio of -0.32 and a beta of 1.40. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.67. The company’s fifty day simple moving average is $0.59 and its 200 day simple moving average is $0.59.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The business had revenue of $0.48 million during the quarter, compared to the consensus estimate of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same period in the previous year, the firm posted $0.12 EPS. As a group, research analysts forecast that Sangamo Therapeutics will post -0.53 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.